Skip to main content
. 2021 Oct 15;8:727412. doi: 10.3389/fmed.2021.727412

Table 2.

Immunomodulatory treatments of patients in the colonic biopsy group.

Diagnosis Immunomodulatory treatment
Yes n (%) Medication(s), number of patients No n (%)
Control (n = 36) 4 (11) Betamethasone, n = 1; methotrexate, n = 1; methotrexate, prednisolone, and sulfasalazine, n =1; prednisolone, n = 1 32 (89)
Diarrhea control (n = 22) 0 (0) N/A 22 (100)
Active LC (n = 9) 0 (0) N/A 9 (100)
LC-HR (n = 6) 1 (17) Budesonide, n = 1 5 (83)
Active CC (n = 16) 4 (25) Budesonide, n = 3; cyclosporine and prednisolone, n = 1 12 (75)
CC-HR (n = 6) 2 (33) Budesonide, n = 1; budesonide and sulfasalazine, n = 1 4 (67)
Active UC (n = 15) 10 (67) Mesalazine, n = 8; mesalazine and methotrexate, n = 1; olsalazine, n = 1 5 (33)
UC remission (n = 12) 6 (50) Balsalazide, n = 1; mesalazine, n = 1; olsalazine, n = 1; sulfasalazine, n = 3 6 (50)

LC, lymphocytic colitis; LC-HR, lymphocytic colitis in histological remission; CC, collagenous colitis; CC-HR, collagenous colitis in histological remission; UC, ulcerative colitis.